Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 13 of the 98 sources its claims cite were checked for support.

Hypermobility spectrum disorders: A review

Open access
Carroll, Matthew B · 2023 · Rheumatology and Immunology Research

Abstract

It remains a clinical challenge identifying when joint hypermobility (JH) is responsible for pain. Previous nomenclature utilized terms such as (benign) joint hypermobility syndrome (JHS) but this was updated in 2017 as advances in genetics provide a basis for nearly all variants of Ehlers-Danlos syndrome (EDS) with the exception of hypermobile EDS (hEDS). New terminology describes hypermobility spectrum disorders (HSDs) as the updated term for JHS. Diagnosis of a subtype of HSDs should be considered in patients who have JH coupled with the presence of secondary musculo-skeletal manifestations (trauma, chronic pain, disturbed proprioception, and other manifestations) and at the exclusion of hEDS. Extra-articular manifestations are common. Treatment relies on management strategies for other chronic pain syndromes with a multidisciplinary approach likely optimal. Lifestyle modifications focus on weight loss and exercise. Physical therapy helps strengthen periarticular muscles, improving mobility. Pharmacologic therapies focus on judicious use of non-steroidal anti-inflammatory drugs and acetaminophen. Serotonin and norepinephrine reuptake inhibitor may help widespread pain. Avoidance of opioids remains prudent. The purpose of this review is to provide clinicians the rationale for the update in nomenclature, understand the musculoskeletal and extra-articular manifestations of the subtypes of HSDs, considerations when making the diagnosis, and treatment.

Overview

CoChat Summary

TL;DR

This narrative review summarizes the 2017 reclassification of symptomatic joint hypermobility into hypermobility spectrum disorders (HSDs), excluding hypermobile Ehlers-Danlos syndrome (hEDS), and reviews musculoskeletal and extra-articular manifestations, diagnosis, and management in adults. It emphasizes that HSDs are common, underdiagnosed, and best managed with a multidisciplinary approach focused on exercise, physical therapy, lifestyle modification, and judicious pharmacologic pain control.

Key findings

  • The 2017 nosology replaced outdated terms such as benign joint hypermobility syndrome (BJHS), joint hypermobility syndrome (JHS), and EDS hypermobility type with HSDs; four subtypes are described: generalized (G-HSD), peripheral (P-HSD), localized (L-HSD), and historical (H-HSD). Diagnosis requires joint hypermobility plus secondary musculoskeletal manifestations and exclusion of hEDS, which still has no known genetic marker.
  • Screening and examination: the 5-Part Questionnaire has reported sensitivity 84% and specificity 85%; for adults, a Beighton score ≥4/9 is suspicious for generalized joint hypermobility.
  • Epidemiology: combined prevalence of HSDs and hEDS is 1 in 600 to 1 in 900; BJHS prevalence was about 3%–4% of the general population, affecting 3.3% of women and 0.6% of men. GJH prevalence varies widely: 32.5% in girls and 18.1% in boys under 19, 11%–12.5% or 12.5%–26% among college students, and 64.9%–72% among professional dancers.
  • Extra-articular manifestations are common, including fatigue up to 84% and dysautonomia up to 75%; strongest associations include orthostasis, functional gastrointestinal disorders, and pelvic/bladder dysfunction. Treatment is multidisciplinary, with lifestyle modification, exercise, physical therapy, NSAIDs/acetaminophen, SNRIs or low-dose TCAs, and avoidance of opioids; a randomized trial of 100 adults found high-load shoulder strengthening statistically superior to low-load strengthening for self-reported function after 16 weeks.

Methods

  • Narrative review focused on patients 18 years of age or older, synthesizing prior literature, the 2017 Ehlers-Danlos Society nosology, and clinical experience.
  • No systematic search strategy, inclusion criteria, or formal quality appraisal is described in the text.
  • The review summarizes diagnostic tools (5PQ, Beighton score), HSD subtypes, epidemiology, pathophysiology, clinical manifestations, and management strategies, including selected interventional studies.

Limitations

  • The paper states that management is limited by uneven access to specialists familiar with HSDs; a Scottish survey found expertise concentrated in higher levels of care, with 80% of respondents citing lack of access to external training. It also notes that patients may struggle to trust providers after years of diagnostic delay and misdiagnosis.
  • The paper states that rigorous studies evaluating lifestyle interventions are lacking, that pathophysiology and mechanisms linking HSDs to extra-articular manifestations require further investigation, and that epidemiology is hampered by changing nosology, differing measurement instruments, and heterogeneous study populations.
  • Evident from the text: this is a narrative review without a described systematic search or quality appraisal, and treatment recommendations often borrow from older nomenclature or from management of other chronic pain syndromes; several cited intervention studies are small (e.g., 27, 21, 14, and 100 participants).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2478/rir-2023-0010

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

10 Valid · 1 Not valid · 61 Not checked · 11 Own results and interpretations

29 more claims

Create a free account to see all 83 claims and to verify the 85 references still open.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 34

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 63 references

Research works printed but not linked: 1

  1. Bravo J, Sanhueza FG, Hakim AJ. Cardiovascular autonomic dysfunction and chronic fatigue in fibromyalgia and joint hypermobility syndrome. In: Hypermobility, Fibromyalgia and Chronic Pain. London: Churchill Livingstone. Elsevier, 2010:69-82.

Cited by

See all 45

Metadata

Authors
Carroll, M. B.
Affiliations
Singing River Health System (US)
Corresponding author
Carroll, Matthew B
Venue
Rheumatology and Immunology Research
Published
2023-06-01
Volume
4
Issue
2
Pages
60-68
ISSN
2719-4523 (ISSN-L)
OpenAlex
W4385147201
Cited by
45
References
63
Citations by year
2026: 14 · 2025: 18 · 2024: 13
FWCI
7.46
Type
journal article
Language
en
Open access
Locations
  • Rheumatology and Immunology Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
  • Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
Keywords
hypermobility spectrum disorders, joint hypermobility, Ehlers-Danlos syndrome, hypermobile Ehlers-Danlos syndrome, benign joint hypermobility syndrome, nomenclatural changes, chronic musculoskeletal pain, extra-articular manifestations, proprioception, multidisciplinary management, physiotherapy, physical activity, weight loss, nonsteroidal anti-inflammatory drugs, paracetamol, serotonin-norepinephrine reuptake inhibitors, opioid avoidance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypermobility spectrum disorders: A review. https://app.cochat.ai/papers/10.2478/rir-2023-0010
The paper
Carroll, M. B. (2023). Hypermobility spectrum disorders: A review. Rheumatology and Immunology Research. https://doi.org/10.2478/rir-2023-0010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.